SERMs: all 411 studies that test it
Page 5 of 5. Open to participants first (37), then studies with results posted, then the rest; newest registration first within each.
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerCompletedNCT00002582Phase 3
- Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast CancerCompletedNCT00002581Phase 3
- Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast CancerCompletedNCT00002580Phase 3
- Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast CancerCompletedNCT00002579Phase 3
- Tamoxifen in Treating Women With High-Risk Breast CancerCompletedNCT00002542Phase 3
- Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast CancerCompletedNCT00002529Phase 3
- Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast CancerCompletedNCT00002528Phase 3
- Adjuvant Hormone Therapy in Treating Women With Operable Breast CancerStatus unknownNCT00002460Phase 3
- The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by EndometriosisCompletedNCT00001848Phase 2
- A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With OsteosarcomaCompletedNCT00001436Phase 1
- Tamoxifen StudyCompletedNCT00000529Phase 3